Eligible patients for omalizumab include subjects not adequately controlled by high ICS dosages and experiencing frequent asthma exacerbations, with positive skin prick test and/or RAST (radioallergosorbent test) for perennial allergens, serum IgE levels ranging from 30 to 1500 IU/m, and a forced expiratory volume in one second (FEV1) less than 80% of the predicted volume [105]. This evidence concerns the gene IGHE and asthma.